James D. Perkins, Jeffrey B. Halldorson, Ramasamy Bakthavatsalam, Oren K. Fix, Robert L. Carithers, Jorge D. Reyes – 28 January 2009 – Studies have shown that liver transplantation offers no survival benefits to patients with Model for End‐Stage Liver Disease (MELD) scores ≤ 14 in comparison with remaining on the waitlist. The consensus of a 2003 transplant community national conference was that a minimum MELD score should be required for placement on the liver waitlist, but no minimum listing national policy was enacted at that time.

Adam Davis, Philip Rosenthal, David Glidden – 28 January 2009 – Nine to twenty‐nine percent of pediatric liver transplant recipients require retransplantation. No previous pediatric study has proposed a prognostic scoring system. We have used the United Network for Organ Sharing transplantation database to conduct a retrospective cohort study of patients who were less than 18 years of age when they received their retransplant (n = 1130).

Mansour A. Parsi, Jason Guardino, John J. Vargo – 28 January 2009

Elizabeth E. Powell, Michael J. Waters, Julie R. Jonsson – 28 January 2009

M. Isabel Fiel, Thomas Schiano – 28 January 2009

Julia L. Newton – 28 January 2009

Myron John Tong, Carlos Hsien, Leeyen Hsu, Hai‐En Sun, Lawrence M. Blatt – 28 January 2009

International Consensus Group for Hepatocellular Neoplasia – 28 January 2009

Itay Shalev, Kit Man Wong, Katharina Foerster, Yi Zhu, Cecilia Chan, Asif Maknojia, Jianhua Zhang, Xue‐Zhong Ma, Xiao Chun Yang, Julia Fang Gao, Hao Liu, Nazia Selzner, David A. Clark, Oyedele Adeyi, M. James Phillips, Reginald R. Gorczynski, David Grant, Ian McGilvray, Gary Levy – 28 January 2009 – Fulminant viral hepatitis (FH) remains an important clinical problem in which the underlying pathogenesis is not well understood.

Jasmin T. Ney, Thomas Schmidt, Christian Kurts, Qi Zhou, Dawid Eckert, Dean W. Felsher, Hubert Schorle, Percy Knolle, Thomas Tüting, Winfried Barchet, Reinhard Büttner, Andreas Limmer, Ines Gütgemann – 28 January 2009 – The reason the adaptive immune system fails in advanced liver tumors is largely unclear. To address this question, we have developed a novel murine model that combines c‐myc–induced autochthonous tumorigenesis with expression of a cognate antigen, ovalbumin (OVA).